| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| BMGLBasel Medical Group Ltd Ordinary Shares | 15.59M | 0.83 | 7.55 | 3.6% | 20.62% | 31.77% | 16.04% | 0.57 |
| Jun 2022 | Jun 2023 | Jun 2024 | |
|---|---|---|---|
| Revenue | 10.66M | 9.7M | 10.05M |
| Revenue Growth % | - | -0.09% | 0.04% |
| Medical Costs & Claims | 2.18M | 2.34M | 2.25M |
| Medical Cost Ratio % | - | - | - |
| Gross Profit | 8.48M | 7.36M | 7.8M |
| Gross Margin % | - | - | - |
| Gross Profit Growth % | - | -0.13% | 0.06% |
| Operating Expenses | 6.01M | 5.36M | 5.61M |
| OpEx / Revenue % | - | - | - |
| Depreciation & Amortization | 575.92K | 557.13K | 528.73K |
| Combined Ratio % | - | - | - |
| Operating Income | 2.47M | 2M | 2.2M |
| Operating Margin % | - | - | - |
| Operating Income Growth % | - | -0.19% | 0.1% |
| EBITDA | 3.05M | 2.56M | 2.72M |
| EBITDA Margin % | - | - | - |
| Interest Expense | 320.87K | 238.6K | 176.24K |
| Non-Operating Income | -233.12K | -367.25K | -385.69K |
| Pretax Income | 2.39M | 2.13M | 2.4M |
| Pretax Margin % | - | - | - |
| Income Tax | 408.48K | 348.28K | 331.76K |
| Effective Tax Rate % | - | - | - |
| Net Income | 1.98M | 1.78M | 2.07M |
| Net Margin % | - | - | - |
| Net Income Growth % | - | -0.1% | 0.16% |
| EPS (Diluted) | 0.11 | 0.10 | 0.11 |
| EPS Growth % | - | -0.14% | 0.16% |
| EPS (Basic) | 0.11 | 0.10 | 0.11 |
| Diluted Shares Outstanding | 18.75M | 18.75M | 18.75M |
| Jun 2022 | Jun 2023 | Jun 2024 | |
|---|---|---|---|
| Total Assets | 16.85M | 15.38M | 16.31M |
| Asset Growth % | - | -0.09% | 0.06% |
| Total Investment Assets | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 |
| Short-Term Investments | 0 | 0 | 0 |
| Total Current Assets | 15.67M | 14.77M | 16.17M |
| Cash & Equivalents | 1.56M | 1.22M | 1.95M |
| Receivables | 1000K | 1000K | 1000K |
| Other Current Assets | 0 | 0 | 1.59M |
| Goodwill & Intangibles | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| PP&E (Net) | 1.18M | 578.78K | 57.97K |
| Other Assets | 0 | 0 | 0 |
| Total Liabilities | 13.14M | 9.89M | 8.75M |
| Total Debt | 10.15M | 7.21M | 4.29M |
| Net Debt | 8.59M | 6M | 2.34M |
| Long-Term Debt | 5.31M | 3.4M | 1.58M |
| Short-Term Debt | 3.63M | 3.22M | 2.68M |
| Total Current Liabilities | 7.19M | 6.47M | 7.16M |
| Accounts Payable | 1.08M | 1.46M | 829.32K |
| Deferred Revenue | 0 | 0 | 0 |
| Other Current Liabilities | 405.5K | 490.73K | 458.31K |
| Deferred Taxes | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 |
| Total Equity | 3.71M | 5.49M | 7.56M |
| Equity Growth % | - | 0.48% | 0.38% |
| Shareholders Equity | 3.71M | 5.49M | 7.56M |
| Minority Interest | 0 | 0 | 0 |
| Retained Earnings | 3.71M | 5.49M | 7.56M |
| Common Stock | 8 | 8 | 24.46M |
| Accumulated OCI | 0 | 0 | -24.46M |
| Return on Equity (ROE) | 0.53% | 0.39% | 0.32% |
| Return on Assets (ROA) | 0.12% | 0.11% | 0.13% |
| Equity / Assets | - | - | - |
| Debt / Equity | 2.74x | 1.31x | 0.57x |
| Book Value per Share | 0.20 | 0.29 | 0.40 |
| Tangible BV per Share | - | - | - |
| Jun 2022 | Jun 2023 | Jun 2024 | |
|---|---|---|---|
| Cash from Operations | 2.79M | 2.6M | 2.51M |
| Operating CF Growth % | - | -0.07% | -0.03% |
| Operating CF / Revenue % | - | - | - |
| Net Income | 2.39M | 2.13M | 2.4M |
| Depreciation & Amortization | 575.92K | 557.13K | 528.73K |
| Stock-Based Compensation | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 |
| Other Non-Cash Items | -251.26K | -375.51K | -419.19K |
| Working Capital Changes | 81.37K | 286.8K | -4.82K |
| Cash from Investing | -88.5K | -6.16K | -7.92K |
| Capital Expenditures | -88.5K | -6.16K | -7.92K |
| Acquisitions | 0 | 0 | 0 |
| Purchase of Investments | 0 | 0 | 0 |
| Sale/Maturity of Investments | 0 | 0 | 0 |
| Other Investing | 0 | 0 | 0 |
| Cash from Financing | -12.92M | -2.94M | -1.77M |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 |
| Stock Issued | 0 | 0 | 0 |
| Debt Issuance (Net) | -1000K | -1000K | -1000K |
| Other Financing | -10.86M | 325 | 1.16M |
| Net Change in Cash | -10.22M | -346.24K | 733.61K |
| Exchange Rate Effect | 0 | 0 | 0 |
| Cash at Beginning | 11.78M | 1.56M | 1.22M |
| Cash at End | 1.56M | 1.22M | 1.95M |
| Free Cash Flow | 2.7M | 2.59M | 2.5M |
| FCF Growth % | - | -0.04% | -0.04% |
| FCF Margin % | - | - | - |
| FCF per Share | 0.14 | 0.14 | 0.13 |
| Metric | 2021 | 2022 | 2023 |
|---|---|---|---|
| Combined Ratio | 76.79% | 79.36% | 78.16% |
| Medical Cost Ratio | 20.44% | 24.09% | 22.37% |
| Return on Equity (ROE) | 53.38% | 38.79% | 31.77% |
| Return on Assets (ROA) | 11.74% | 11.07% | 13.08% |
| Equity / Assets | 21.99% | 35.69% | 46.37% |
| Book Value / Share | 0.2 | 0.29 | 0.4 |
| Debt / Equity | 2.74x | 1.31x | 0.57x |
| Revenue Growth | - | -8.98% | 3.6% |
Basel Medical Group Ltd Ordinary Shares (BMGL) has a price-to-earnings (P/E) ratio of 7.5x. This may indicate the stock is undervalued or faces growth challenges.
Basel Medical Group Ltd Ordinary Shares (BMGL) grew revenue by 3.6% over the past year. Growth has been modest.
Yes, Basel Medical Group Ltd Ordinary Shares (BMGL) is profitable, generating $2.1M in net income for fiscal year 2023 (20.6% net margin).
Basel Medical Group Ltd Ordinary Shares (BMGL) has a return on equity (ROE) of 31.8%. This is excellent, indicating efficient use of shareholder capital.
Basel Medical Group Ltd Ordinary Shares (BMGL) has a combined ratio of 78.2%. A ratio below 100% indicates underwriting profitability.